Abstract:Gastrointestinal cancer has a high incidence in China, especially upper gastrointestinal cancer (esophageal and gastric cancer). Although the incidence has been declining in recent years, the annual incidence of new cases accounts for more than 50% of global cases, and the incidence of colorectal cancer in big cities like Beijing and Shanghai is increasing annually but the mortality rate has not yet increased significantly. Gradual implementation and promotion of multidisciplinary team (MDT) reduced the mortality of gastrointestinal tumors, but this change is not obvious. Successful clinical studies of immune checkpoint inhibitors [programmed death-1 (PD-1), programmed death ligand 1 (PD-L1)] for esophageal and gastric cancer have changed clinical treatment strategies. The overall survival of advanced patients has improved but the comprehensive treatment of locally advanced patients warrants further research. In addition to the microsatellite instability high (MSI-H) population, few drugs have changed the clinical outcome of colorectal cancer in the past decade, which makes it difficult to affect the prognosis of patients. Clinical research on MDT is difficult to conduct, resulting in less data accumulation in this field. The heterogeneity of gastrointestinal tumors is relatively strong and precise treatment should be the direction of future development. In this regard, several studies have been conducted and developed rapidly in recent years in China, including those on MSI-H, human epidermal growth factor receptor 2 (HER2), c-mesenchymal-epithelial transition factor (c-MET), B-Raf proto-oncogene serine/threonine kinase (BRAF), rat sarcoma virus (RAS), fibroblast growth factor receptors (FGFR) and polymerases epsilon (POLE). The selection of immunotherapy markers, as well as the discovery of efficacy and prognostic markers, are also clinicians' concerns. Several articles presented in this issue reflect the research carried out by Chinese researchers based on clinical problems. These concerns of clinicians would impact the clinical practice. However, due to the limitation of time and level, the findings cannot fully reflect the current level of gastrointestinal cancer research in China which is expected to develop rapidly in the future.

Current status and prospect of basic researches on gastrointestinal surgery

Present status and perspective of basic research on gatroenterological malignant tumors

Research Status and Progress on Treatment of Advanced Gastric Cancer

Progress and prospects in experimental study of gastric surgery

Status and prospect of clinical research of minimally invasive surgery for gastrointestinal tumors

Progress in Clinical Research of Gastric Cancer

Surgical treatment of gastric cancer: Current status and future directions

[Evolution and Prospect of Colorectal Anastomosis].

Research Progress in Gastrointes tinal Stromal Tumors Treatment

[Research progress and prospect of gastric cancer surgery in 2021]

Hotspots in basic and translational research of gastric cancer

Consideration on Relative Issues of Gastrointestinal Stromal Tumor

Current Status of Clinical Research on Gastric Cancer in China

Research Improvements and Related Hot Issues of Surgical Treatment on Locally Advanced Rectal Cancer

Concerned about the issue of gastrointestinal tumor targeted therapy

Research progress and perspective of immunotherapy for gastrointestinal malignant tumors

Current clinical trials on gastric cancer surgery in China

Current Status and Challenges of Gastrointestinal Cancer Treatment in China

[Promote the High-Quality Development of Gastrointestinal Surgery with Technological Concept Innovation].

Research progress in targeted therapy and immunotherapy for gastric cancer

Recent Advances in the Diagnosis, Staging, Treatment, and Prognosis of Advanced Gastric Cancer: A Literature Review